Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1679-1687

  Xue, Cong ^a,b   Wang, Xi ^a,b   Peng, Roujun ^a,b   Shi, Yanxia ^a,b   Qin, Tao ^a,b   Liu, Donggen ^a,b   Teng, Xiaoyu ^a,b   Wang, Shusen ^a,b   Zhang, Li ^a,b   Yuan, Zhongyu ^a,b  

^a State Key Laboratory of Oncologyin in South China   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHINA; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHINA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84865706969     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02339.x     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243-50.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502.
5. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10.
6. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-8.
7. Tang P, Wang J, Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 2008; 39: 506-13.
8. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-74.
9. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer I 2009; 101: 736-50.
10. Kim RG, Kim EK, Kim HA et al. Prognostic significance of molecular subtype in T1N0M0 breast cancer: Korean experience. Eur J Surg Oncol 2011; 37: 629-34.
11. Zhao J, Liu H, Wang M et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 2009; 100: 89-94.
12. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 2009; 20: 628-35.
13. Yang XR, Sherman ME, Rimm DL et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439-43.
14. Kurebayashi J, Moriya T, Ishida T et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 2007; 16(Suppl 2): S72-7.
15. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer Am Cancer Soc 2007; 109: 1721-8.
16. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45.
17. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
18. Lund MJ, Trivers KF, Porter PL et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Tr 2009; 113: 357-70.
19. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast 2008; 17: 323-34.
20. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-7.
21. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217-26.
22. Da Silva L, Clarke C, Lakhani SR. Demystifying basal-like breast carcinomas. J Clin Pathol 2007; 60: 1328-32.
23. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973-9.
24. Rakha EA, El-Sayed ME, Green AR et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25: 4772-8.
25. Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984; 2: 1102-9.
26. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15: 593-602.
27. Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-9.
28. Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-6.
29. de Azambuja E, Cardoso F, de Castro G, Jr. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Brit J Cancer 2007; 96: 1504-13.
30. Abe O, Abe R, Enomoto K et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
31. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005; 330: 217.
32. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
33. Wang S, Shi Y, Yuan Z et al. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol 2012; 29: 547-53.
34. Colleoni M, Cole BF, Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28: 2966-73.